Gene-editing therapy for sickle-cell disease shows promise
- Crispr Therapeutics’ stock soars 17% in premarket trade after positive FDA panel meeting
- FDA sets Dec. 8 target action date for possible approval of gene-editing therapy for sickle-cell disease
- Analysts predict exa-cel is very likely to be approved
- Sickle-cell disease affects 70,000 to 100,000 Americans annually
- Crispr’s stock has fallen 4% YTD, while Vertex has gained 25% and S&P 500 has gained 9%
Crispr Therapeutics AG’s stock rallied 17% in premarket trade after a positive meeting of the FDA advisory panel on the gene-editing drug exa-cel. The therapy, developed by Crispr and Vertex Pharmaceuticals, aims to treat sickle-cell disease. The FDA has set a target action date of December 8 for possible approval. Analysts believe exa-cel is very likely to be approved, describing the meeting as a ‘clearing event’ for Vertex and a ‘nice win’ for Crispr. Sickle-cell disease affects an estimated 70,000 to 100,000 Americans annually. Crispr’s stock has fallen 4% year-to-date, while Vertex has gained 25% and the S&P 500 has gained 9%.
Factuality Level: 7
Factuality Justification: The article provides information about Crispr Therapeutics AG’s stock rally after a positive meeting of an FDA advisory panel on the gene-editing drug exa-cel. It mentions the target action date for possible approval of the treatment and includes quotes from analysts. The article also provides background information on sickle-cell disease and the stock performance of Crispr and Vertex Pharmaceuticals. Overall, the article seems to provide factual information without significant bias or inaccuracies.
Noise Level: 7
Noise Justification: The article provides relevant information about Crispr Therapeutics AG’s stock rally after a positive FDA advisory panel meeting on the gene-editing drug exa-cel. It mentions the potential approval of the treatment for sickle-cell disease and the estimated number of Americans affected by the disease. However, the article lacks scientific rigor and intellectual honesty as it does not provide any evidence or data to support the claims made by the analysts. It also does not explore the consequences of the potential approval on those who bear the risks or provide actionable insights or solutions.
Financial Relevance: Yes
Financial Markets Impacted: Crispr Therapeutics AG (CRSP), Vertex Pharmaceuticals (VRTX)
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to the financial market as it discusses the stock rally of Crispr Therapeutics AG and the potential approval of their gene-editing drug for sickle-cell disease. However, there is no mention of any extreme event.
Public Companies: Crispr Therapeutics AG (CRSP), Vertex Pharmaceuticals (VRTX)
Key People:
Reported publicly:
www.marketwatch.com 
